| CAS NO: | 76684-89-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Molecular Weight (MW) | 314.38 |
|---|---|
| Formula | C15H26N2O5 |
| CAS No. | 76684-89-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 62 mg/mL (197.2 mM) |
| Water: 2 mg/mL (6.4 mM) | |
| Ethanol: 62 mg/mL (197.2 mM) | |
| Solubility (In vivo) | Saline: 2mg/mL |
| Synonyms | NSC-694279; EP-475; E64-C; NSC 694279; EP 475; E64 C; NSC694279; EP475; E64C; Loxistatin Acid; |
| In Vitro | In vitro activity: Loxistatin Acid (E-64C), as a thiol protease inhibitor, inhibits calpain activity in intact platelets. E-64C inhibits β-secretase activity in regulated secretory vesicles of neuronal chromaffin cells, and decrease Aβ production, indicating a therapeutic strategy for Alzheimer's disease. |
|---|---|
| In Vivo | In pectoral muscle of dystrophic chickens, Loxistatin Acid (E-64C) normalizes the increased activities of cathepsin B and cathepsin H. E-64C inhibits ischemic degradation of cerebral proteins following occlusion of the middle cerebral artery in rats. |
| Animal model | Male Sprague-Dawley rats. |
| Formulation & Dosage | Dissolved in a small amount of saturated bicarbonate solution and then diluted with 0.9% NaCl saline; 400 mg/kg; i.p. injection |
| References | Biochem Biophys Res Commun. 1989 Jan 31;158(2):432-5; J Neurosci Res. 2003 Nov 1;74(3):393-405; J Biol Chem. 1991 Aug 5;266(22):14771-7. |
m.cnreagent.com